Y-Intercept (HK)’s Cabaletta Bio CABA Stock Holding History

Y-Intercept (HK)’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-18,727	Closed	-$140K	–	1340
2024 Q2	$140K	Buy	+18,727	New	+$230K	0.01%	1220

Other funds holding CABA

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Y-Intercept (HK)'s CABA Position: Q3 2024 in Review

Y-Intercept (HK) sold out of Cabaletta Bio (CABA) in Q3 2024, closing a stake of 18,727 shares — an estimated $140K sold.

Y-Intercept (HK) first reported a position in CABA in Q2 2024 and held it in 1 quarter. The position peaked at $140K in Q2 2024. 120 funds tracked by Wall St. Rank hold CABA as of Q3 2024.

Y-Intercept (HK) reported no remaining Cabaletta Bio position as of Q3 2024 after selling out during the quarter.
Y-Intercept (HK) sold 18,727 Cabaletta Bio shares in Q3 2024, an estimated $140K.
Y-Intercept (HK) first reported a position in Cabaletta Bio in Q2 2024 and held it in 1 quarter.
Y-Intercept (HK)'s Cabaletta Bio position peaked at $140K in Q2 2024.
120 funds tracked by Wall St. Rank held Cabaletta Bio as of Q3 2024.

Based on Y-Intercept (HK)'s 13F filing for Q3 2024, filed 15 Nov 2024.